Date:1/30/2013

others, statements about the Company's expectations with respect to its proposed offering, including its intention to offer and sell shares, the closing of the offering and the Company's intended use of proceeds from the offering. Such statements are based on the Company's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as those risks discussed in NewLink's Annual Report on Form 10-K for the year ended December 31, 2011, in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012, and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release represent NewLink's views as of the date of this press release. NewLink anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink's views as of any date subsequent to the date of this press release.

Contact:
Gordon Link
Chief Financial Officer
515-598-2925
glink@linkp.com

'/>"/>

SOURCE NewLink Genetics Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock
2. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
3. Lota S. Zoth joins NewLinks Board of Directors; heads Audit Committee
4. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
5. Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
6. Submit Questions to Nobel Laureates and Other Experts about Genetics and Society
7. The International Serious Adverse Event Consortium and UC San Diego To Collaborate On Research Into The Genetics Of Drug Induced Renal Injury
8. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
9. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
10. Response Genetics, Inc. to Release Second Quarter Financial Results and Host Conference Call on August 14, 2012
11. Genelex Receives First Patent on Business Methods for Pharmacogenetics